| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools.
|
|
Today’s Big NewsFeb 11, 2025 |
| By Gabrielle Masson After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, when combined with Xtandi, reduced prostate cancer progression by 49% compared with Xtandi alone. |
|
|
|
By Fraiser Kansteiner Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the company believes could be finally nearing a “growth expansion phase” despite slow sales so far in the U.S. |
By Nick Paul Taylor Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, Novartis has struck a deal to buy Anthos for $925 million upfront to add the clot-busting prospect to its late-phase pipeline. |
By Kevin Dunleavy During its quarterly earnings presentation, Vertex said that it expects to begin shipping newly approved non-opioid pain reliever Journavx by the end of this month and is working to secure “broad stocking agreements” with national and regional pharmacy chains. |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights.
|
|
By Gabrielle Masson A new initiative rolled out under President Donald Trump’s administration is cutting billions from grants for "indirect costs" tied to biomedical research, such as facilities, equipment and administrative expenses. |
By Fraiser Kansteiner The FDA earlier this month issued separate warning letters to Chinese drug ingredient firms Nuowei Chemistry and Innovation Pharmaceutical. The write-ups cover the quality control and testing shortfalls that led to both companies receiving U.S. import bans in late January. |
By Andrea Park Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during Sunday night’s broadcast, according to TV advertising analyst EDO, but also ranked in the top 10 of all Super Bowl ads across categories. |
By Fraiser Kansteiner Merck KGaA is in advanced talks to acquire cancer and rare disease specialist SpringWorks, which has a market value of around $3 billion, Reuters reported Monday. Merck KGaA confirmed the talks but said it's not certain a deal will come together. |
By Conor Hale Insilico also disclosed it’s begun chasing new therapeutic areas in obesity and muscle wasting conditions as well as in nonaddictive painkillers. |
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Nick Paul Taylor Older millennials, take note: Bayer is worried about your heart health. The drugmaker set out its concerns in an ad for aspirin, showing how people are putting themselves in danger by denying that they are now among the age group at risk of cardiovascular disease. |
By Conor Hale Its Tile-T20 cartridge and the wearable Tasso Mini push-button lancet are designed to collect four precise blood samples at a specific volume. |
By Nick Paul Taylor Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as Octavian Therapeutics to align with its “growth ambitions and its transition to a privately held company.” |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we dig into the 10 biggest potential drug launches of 2025, predicted to rake in a combined $29 billion in annual sales by the end of the decade. |
|
|---|
|
|
|
Tuesday, February 25, 2025 | 2pm ET / 11am PT Discover how a direct-to-individual approach to real-world data (RWD) is transforming obesity treatment insights. Learn how the right engagement strategies enable effective tracking of GLP-1 use, adherence, and outcomes, leveraging wearable and multi-modal data for predictive modeling and early interventions. Join us to explore new ways to enhance patient understanding. Register now.
|
|
| WhitepaperThis paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
